{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T12:03:28Z","timestamp":1775217808964,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s12328-025-02275-z","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:29:34Z","timestamp":1767781774000},"page":"362-366","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term complete response of early gastric cancer to nivolumab: report of a case with disease-free survival for six years"],"prefix":"10.1007","volume":"19","author":[{"given":"Akinori","family":"Tsujimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohei","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kunishige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Soga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sukegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"2275_CR1","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: A population-based modelling study. EClinicalMedicine. 2022;47:101404.","journal-title":"EClinicalMedicine"},{"key":"2275_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"2275_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138.","journal-title":"Ann Oncol"},{"key":"2275_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"2275_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566\u201376.","journal-title":"Nat Med"},{"key":"2275_CR6","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377.","journal-title":"Lancet Oncol"},{"key":"2275_CR7","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390:1756\u201369.","journal-title":"N Engl J Med"},{"key":"2275_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8:765\u201372.","journal-title":"Int Immunol"},{"key":"2275_CR9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The Blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"2275_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"2275_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u201323.","journal-title":"Cell"},{"key":"2275_CR12","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa1312547","volume":"371","author":"WC Black","year":"2014","unstructured":"Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National lung screening trial. N Engl J Med. 2014;371:1793\u2013802.","journal-title":"N Engl J Med"},{"key":"2275_CR13","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1038\/s41416-020-01053-7","volume":"123","author":"A Junttila","year":"2020","unstructured":"Junttila A, Helminen O, Vayrynen JP, et al. Immunophenotype based on inflammatory cells, PD-1\/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer. Br J Cancer. 2020;123:1625\u201332.","journal-title":"Br J Cancer"},{"key":"2275_CR14","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.3390\/biomedicines11072003","volume":"11","author":"XJ Chen","year":"2023","unstructured":"Chen XJ, Wei CZ, Lin J, et al. Prognostic significance of PD-L1 expression in gastric cancer patients with peritoneal metastasis. Biomedicines. 2023;11:2003.","journal-title":"Biomedicines"},{"key":"2275_CR15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000509033","volume":"99","author":"Y Ubukata","year":"2021","unstructured":"Ubukata Y, Ogata K, Sohda M, et al. Role of PD-L1 expression during the progression of submucosal gastric cancer. Oncology. 2021;99:15\u201322.","journal-title":"Oncology"},{"key":"2275_CR16","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, et al. First-Line nivolumab plus chemotherapy for advanced Gastric, gastroesophageal Junction, and esophageal adenocarcinoma: 3-Year Follow-Up of the phase III checkmate 649 trial. J Clin Oncol. 2024;42:2012\u201320.","journal-title":"J Clin Oncol"},{"key":"2275_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s10120-011-0075-8","volume":"15","author":"M Takao","year":"2012","unstructured":"Takao M, Kakushima N, Takizawa K, et al. Discrepancies in histologic diagnoses of early gastric cancer between biopsy and endoscopic mucosal resection specimens. Gastric Cancer. 2012;15:91\u20136.","journal-title":"Gastric Cancer"},{"key":"2275_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41416-019-0515-5","volume":"121","author":"K Yamashita","year":"2019","unstructured":"Yamashita K, Iwatsuki M, Harada K, et al. Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer. 2019;121:278\u201380.","journal-title":"Br J Cancer"},{"key":"2275_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/0976-9668.82318","volume":"2","author":"T Jessy","year":"2011","unstructured":"Jessy T. Immunity over inability: the spontaneous regression of cancer. J Nat Sci Biol Med. 2011;2:43\u20139.","journal-title":"J Nat Sci Biol Med"},{"key":"2275_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.3346\/jkms.2010.25.10.1518","volume":"25","author":"HS Lee","year":"2010","unstructured":"Lee HS, Cheung DY, Kim JI, et al. A case of spontaneous regression of advanced gastric cancer. J Korean Med Sci. 2010;25:1518\u201321.","journal-title":"J Korean Med Sci"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02275-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02275-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T11:25:14Z","timestamp":1775215514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02275-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02275-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"2 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}